Because many patients with IBD receive immunosuppressive drugs, doctors have wondered whether those patients might be more susceptible to COVID-19, or its effects. On the other hand, immunomodulatory therapies might also suppress the hyperinflammatory cytokine response associated with the most severe presentations of COVID-19.
Dr. Lorenzo Norsa and colleagues observed 522 IBD patients in their clinic at the Papa Giovanni XXIII Hospital...
- Read Full Article...
- 5 comments
- 10,510 views